← Eichor
Study identifier: NCT06451172 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis

Condition: Bacterial Keratitis · Antibiotic-resistant Bacteria · Infections, Bacterial  ·  Sponsor: Eye & ENT Hospital of Fudan University

PhaseEARLY_Phase 1
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.

This description comes directly from the study's public registry record.

Talk to the study team

Jiaxu Hong, M.D., Ph.D  ·  +86-021-64377134  ·  chengmingruicmr@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Eye & ENT Hospital of Fudan UniversityShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06451172